| (Values in U.S. Thousands) | Dec, 2017 | Sep, 2017 | Jun, 2017 | Mar, 2017 | Dec, 2016 |
| Sales | 930 | 390 | 700 | 590 | 5,970 |
| Sales Growth | +138.46% | -44.29% | +18.64% | -90.12% | +2,032.14% |
| Net Income | -5,780 | -5,980 | -6,120 | -5,140 | -70 |
| Net Income Growth | +3.34% | +2.29% | -19.07% | -7,242.86% | +99.02% |
Psivida Corp Com (PSDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
pSivida Corp., a specialty pharmaceutical company, combines existing drugs with its sustained release delivery technologies to develop transformational products primarily in ophthalmology. pSivida's two proprietary technology systems are Durasert and Tethadur. Durasert delivers specific quantities of drugs at controlled rates for predetermined periods of time from weeks to months. pSivida has developed three of the four sustained delivery release devices for retinal diseases that have been approved in either the US or Europe, the most recent being ILUVIEN', partnered with Alimera Sciences and approved in multiple EU countries. Independently, pSivida is developing an injectable, bioerodible product to treat glaucoma and ocular hypertension. Tethadur is a protein, peptide and antibody delivery system.